Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2005 Aug;91(8):997-9.
doi: 10.1136/hrt.2004.053579.

N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration

S J Shalansky, G E Pate, A Levin, J G Webb
Editorial

N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration

S J Shalansky et al. Heart. 2005 Aug.

Abstract

Dose and route of administration of N-acetylcysteine are key factors to consider when evaluating whether this agent is effective in preventing radiocontrast induced nephropathy.

PubMed Disclaimer

References

    1. Fishbane S, Durham JH, Marzo K, et al. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. J Am Soc Nephrol 2004;15:251–60. - PubMed
    1. Borgstrom L, Kagedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 1986;31:217–22. - PubMed
    1. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180–4. - PubMed
    1. Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003;362:598–603. - PubMed
    1. Isenbarger DW, Kent SM, O’Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003;92:1454–8. - PubMed

Publication types

MeSH terms